We can’t show the full text here under this license. Use the link below to read it at the source.
Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2)
Tirzepatide improved insulin production and sensitivity in people with type 2 diabetes
AI simplified
Abstract
At week 40, tirzepatide doses resulted in a 96.9-120.4% increase in pancreatic β-cell function compared to an 84.0% increase with semaglutide.
- Tirzepatide significantly improved β-cell function, as indicated by changes, more than semaglutide.
- All doses of tirzepatide resulted in a greater reduction in insulin resistance () compared to semaglutide.
- Tirzepatide 10 and 15 mg led to significant reductions in both fasting C-peptide and fasting glucagon, while semaglutide showed an increase in C-peptide.
- Reductions in HbA1c and body weight were consistently greater with tirzepatide across all levels of baseline β-cell function and insulin resistance.
AI simplified
Key numbers
96.9% to 120.4%
Increase in
Percent change from baseline at week 40 with tirzepatide vs semaglutide.
15.5% to 24.0%
Reduction in
Percent change from baseline at week 40 with tirzepatide vs semaglutide.
−2.09% to −2.46%
HbA1c Reduction
Change from baseline to week 40 for tirzepatide vs semaglutide.